The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    January 2020

  • Pages
    357

  • View Count
    4303

Example Insights

Targeted Protein Degradation Context Targeted Protein Degradation Companies Targeted Protein Degradation Market Landscape Targeted Protein Degradation Developer Landscape
Targeted Protein Degradation - Clinical Trial Analysis Targeted Protein Degradation - Key Opinion Leaders (KOL) Targeted Protein Degradation - Funding and Investments Targeted Protein Degradation - Partnership and Collaborations
Targeted Protein Degradation - Licensing Deals Targeted Protein Degradation - Opportunity Analysis

 

Overview

The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. Owing to various reasons, conventional pharmacological interventions have been severely restricted in terms of accessing protein targets of pathological significance. However, researchers engaged in developing bifunctional protein degrader-based interventions claim that this upcoming class of medicinal compounds possess the capability to access the part of the eukaryotic proteome that was previously considered undruggable. The science behind this innovation revolves around the use of specially designed small molecules that are capable of recruiting the ubiquitin-proteasome system (UPS) to selectively eliminate a target protein, via proteolysis. The applications of this technology in drug discovery are vast. Further, drugs designed / based on this concept are known to demonstrate a remarkable level of selectivity, high potency, oral bioavailability and differentiated pharmacology, when compared to traditional occupancy-based inhibitors. As a result, targeted protein degradation-based therapeutics have generated enthusiasm within the medical science community, thereby, defining a new frontier in the field of medicine. The growing popularity and interest in the therapeutic potential of these molecules is evident across modern scientific literature (500+ related articles on NCBI’s PubMed portal), and from social media chatter (4,000+ tweets posted on the platform, Twitter, over the last three years).

The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago. Over the years, significant progress has been made towards understanding the physiochemical and biological properties of these bifunctional molecules. In fact, a variety of other chemical entities and molecular glues have been developed for the treatment of a variety of clinical conditions, including acute myeloid leukemia, Alzheimer's disease, breast cancer, myelofibrosis, multiple myeloma, Parkinson's disease, prostate cancer, psoriasis, rheumatoid arthritis, and supranuclear palsy. R&D efforts in this field are being supported by novel DNA-encoded libraries and other versatile bioinformatics tools, which are enabling efficient hit discovery and characterization of potential therapeutic leads. So far, investments worth over USD 3.5 billion have been made in this emerging field of research by various private and public investors. In addition, technology developers with expertise in targeted protein degradation are known to have been involved in several big licensing deals. It is also worth mentioning that, in the last 4-5 years, there has been a marked rise in the number of new entrants in this market. Interestingly, several big pharma players are also actively evaluating protein degraders. Although there are no approved protein degrader-based drugs / therapy products in the market yet, we can expect targeted protein degradation to become a major therapeutic modality in the coming decade. 

Scope of the Report

The ‘Targeted Protein Degradation Market: Focus on Technology Platforms and Therapeutics, 2020-2030’ report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics and affiliated technologies, over the next decade. The focus of this study is on specially designed small molecule degraders, including degronimids, endosome targeting chimeras (ENDTACs), epichaperome inhibitors, hydrophobic tags, immuno-modulatory imide drugs (IMiDs), lysosome targeting chimeras (LYTACs), molecular glues, photochemically targeting chimeras (PHOTACs), proteolysis targeting chimeras (PROTACs), protein homeostatic modulators, selective androgen receptor degraders (SARDs), selective estrogen receptor degraders (SERDs), specific and non-genetic IAP-dependent protein erasers (SNIPERs), and specific bromodomain and extra-terminal motif (BET) inhibitors and deubiquitinase (DUB) inhibitors. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape of targeted protein degradation-based therapeutics, providing information on drug / therapy developer(s) (such as year of establishment, company size and location of headquarters), clinical study sponsor(s) and collaborator(s), type of protein degrader (degronimids, ENDTACs, epichaperome inhibitors, hydrophobic tags, IMiDs, LYTACs, molecular glues, PHOTACs, PROTACs, protein homeostatic modulators, SARDs, SERDs, SNIPERs, and specific BET and DUB inhibitors), phase of development (clinical, preclinical, and discovery stage) of product candidates, target indication(s), key therapeutic area(s), type of target protein(s), target enzyme(s) (if available), target signaling pathway (if available), mechanism of action (if available), type of therapy (monotherapy and combination therapy), route of administration (oral, intravenous and others), and information on special drug designations (if any). In addition, the chapter highlights the various technology platforms that are being actively used for the development of targeted protein degraders. 
  • Elaborate profiles of key players that are engaged in the development of targeted protein degraders (shortlisted on the basis of phase of development of pipeline products), featuring a brief overview of the company, its financial information (if available), detailed descriptions of their respective lead drug candidates, and an informed future outlook. Additionally, each drug profile features information on the type of drug, route of administration, target indications, current status of development and a brief summary of its developmental history. 
  • Brief tabulated profiles of industry players (shortlisted on the basis of the number of pipeline products), featuring details on the innovator company (such as year of establishment, location of headquarters, number of employees, and key members of the executive team), recent developments, along with descriptions of their respective drug candidates. 
  • A detailed clinical trial analysis of completed, ongoing and planned studies of various targeted protein degraders, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, enrolled patient population and regional distribution of trials, type of protein degrader, phase of development, study design, leading industry and non-industry players (in terms of number of trials conducted), study focus, target therapeutic area, key indications, and clinical endpoints.
  • An assessment of the relative experience of key opinion leaders (KOLs) within this domain, (shortlisted based on their involvement in various clinical studies), featuring detailed 2X2 matrices (based on the strength and activeness of KOLs), a schematic world map representation (highlighting the geographical locations of eminent scientists / researchers) and an analysis evaluating the (relative) level of expertise of different KOLs, based on parameters such as number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network (based on information available on ResearchGate).
  • An analysis of the partnerships that have been established in the domain, over the period 2014-Q3 2019, covering research agreements, product / technology licensing agreements, mergers / acquisitions, asset purchase agreements, R&D and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and other relevant deals.
  • An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, by companies that are engaged in this field.

One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities for novel technologies designed for the development of targeted protein degraders. Based on the likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided an informed estimate on the evolution of the market over the period 2020-2030. The report features likely distribution of the current and forecasted opportunity across [A] type of protein degrader (degronimids, IMiDs, PROTACs, SARDs, SERDs, and specific BET and DUB inhibitors), [B] therapeutic area (inflammatory disorders, neurological disorders, oncological disorders, respiratory disorders, and other therapeutic areas), [C] route of administration (oral, intravenous and others), [D] key contributing technologies and [E] key geographical regions (North America, Europe and Asia-Pacific). In order to account for future uncertainties associated with the growth of targeted protein degradation market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. 

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outline

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of targeted protein degradation-based drugs market and its likely evolution in the short-mid term and long term.

Chapter 3 is an introductory chapter that highlights important concepts related to protein homeostasis, including a discussion on the UPS for intracellular protein degradation and turnover. It presents an elaborate discussion on the structure and function of ubiquitin, various components of the UPS and key steps involved in the UPS-based protein degradation. Further, the chapter provides an overview of the concept of targeted protein degradation, including details on various protein degraders and their associated pathways and mechanisms of action. The chapter also includes a discussion on the historical evolution, importance, advantages and challenges related to the use of targeted protein degradation as a therapeutic principle. In addition, the chapter describes the key growth drivers and roadblocks related to targeted protein degraders, offering insights on the upcoming trends in the domain.

Chapter 4 includes information on more than 85 targeted protein degraders that are currently being evaluated in different stages of development (both clinical and preclinical / discovery). It features a comprehensive analysis of pipeline molecules based on their types of protein degraders (degronimids, ENDTACs, epichaperome inhibitors, hydrophobic tags, IMiDs, LYTACs, molecular glues, PHOTACs, PROTACs, protein homeostatic modulators, SARDs, SERDs, SNIPERs, and specific BET and DUB inhibitors), phases of development (clinical, preclinical, and discovery stage) of product candidates, target indications, key therapeutic areas, types of target proteins, target enzymes (if available), target signaling pathways (if available), mechanisms of action (if available), types of therapies (monotherapy and combination therapy), route of administration (oral, intravenous and others), and information on special drug designations (if any). Further, the chapter provides information on drug developer(s), highlighting their year of establishment, location of headquarters and company size. In addition, the chapter highlights the various technology platforms that are being actively used for the development of targeted protein degraders.

Chapter 5 features elaborate profiles of key players that are engaged in the development of targeted protein degraders (shortlisted on the basis of phase of development of pipeline products). Each company profile includes a brief overview of the company, its financial information (if available), detailed descriptions of their respective lead drug candidates, and an informed future outlook. Additionally, each drug profile features information on the type of drug, route of administration, target indications, current status of development and a brief summary of its developmental history. Further, the chapter includes tabulated profiles of industry players (shortlisted on the basis of the number of pipeline products), featuring details on the innovator company (such as year of establishment, location of headquarters, number of employees, and key members of the executive team), recent developments, along with descriptions of their respective drug candidates.

Chapter 6 provides a detailed clinical trial analysis of completed, ongoing and planned studies of various targeted protein degraders. The analysis highlights the key trends associated with these clinical studies across various parameters, such as current trial status, trial registration year, enrolled patient population and regional distribution of trials, type of protein degrader, phase of development, study design, leading industry and non-industry players (in terms of number of trials conducted), study focus, target therapeutic area, key indications, and clinical endpoints.

Chapter 7 provides an analysis of KOLs in the field of targeted protein degradation. It features a comprehensive list of principal investigators / study directors of different clinical trials, along with information related to the affiliated research institutes. The chapter features a schematic representation of a world map, highlighting the geographical locations of eminent scientists / researchers who are engaged in clinical research in this domain. It also presents a comparative analysis, highlighting those KOLs who have relatively more experience in this domain. The (relative) level of expertise of different KOLs defined by other analysts / industry experts were compared to the results obtained using a proprietary scoring criteria, which was based on parameters such as number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network (based on information available on ResearchGate).

Chapter 8 features an elaborate analysis and discussion of partnerships / collaborations that have been established in this domain in the period 2014 - 2019. It includes a brief description of various types of partnership models (such as research agreements, product / technology licensing agreements, mergers / acquisitions, asset purchase agreements, R&D and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and others) that have been employed by stakeholders within this domain. It also consists of a schematic representation showcasing the players that have established the maximum number of alliances related to targeted protein degraders. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 9 provides information on funding instances and investments that have been made within the targeted protein degradation domain. The chapter includes details on various types of investments (such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings) received by companies in the period 2014-Q3 2019, highlighting the growing interest of the venture capital community and other strategic investors in this domain.

Chapter 10 features a comprehensive market forecast, highlighting the future potential of novel technologies designed for the development of targeted protein degraders till 2030, based on likely licensing deal structures and agreements that are expected to be signed in the foreseen future. In addition, we estimated the likely distribution of the current and forecasted opportunity across [A] type of protein degrader (degronimids, IMiDs, PROTACs, SARDs, SERDs, and specific BET and DUB inhibitors), [B] therapeutic area (inflammatory disorders, neurological disorders, oncological disorders, respiratory disorders, and other therapeutic areas), [C] route of administration (oral, intravenous and others), [D] key contributing technologies and [E] key geographical regions (North America, Europe and Asia-Pacific).

Chapter 11 is a collection of executive insights of the discussions that were held with various key stakeholders in this market.

Chapter 12 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 14 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Context and Background
3.2. Protein Homeostasis
3.3. Post Translational Protein Modifications
3.4. Ubiquitin and the Ubiquitin Proteasome System (UPS) 
3.4.1. Structure and Functions of Ubiquitin
3.4.2. Overview of the UPS
3.4.2.1. Components of the UPS
3.4.2.2. Ubiquitin-based Protein Degradation Pathway

 

3.5. Therapeutic Applications of the UPS
3.6. Ubiquitin Enzyme Inhibitors
3.6.1. Advantages and Challenges 

3.7. Overview of Targeted Protein Degradation
3.7.1. Historical Development of Protein Degraders
3.7.2. Types of Protein Degraders
3.7.2.1. Proteolysis Targeting Chimeras (PROTACs)
3.7.2.2. Other Chimeric Protein Targeting Molecules
3.7.2.2.1. Endosome Targeting Chimeras (ENDTACs)
3.7.2.2.2. Lysosome Targeting Chimeras (LYTACs)
3.7.2.2.3. Photochemically Targeted Chimeras (PHOTACs)

3.7.2.3. Epichaperome Inhibitors
3.7.2.4. Hydrophobic Tags
3.7.2.5. Immuno-modulatory Imide Drugs (IMiDs)
3.7.2.6. Molecular Glues
3.7.2.7. Protein Homeostatic Modulators
3.7.2.8. Selective Hormone Receptor Degraders (SHRDs)
3.7.2.9. Specific and Non-genetic IAP-dependent Protein Erasers (SNIPERs)
3.7.2.10. Specific Bromodomain and Extra-terminal Motif (BET) Inhibitors and Deubiquitinase (DUB) Inhibitors

3.8. Growth Drivers and Roadblocks
3.9. Recent Developments and Upcoming Trends
 
4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Targeted Protein Degradation-based Therapeutics and Technologies: Development Pipeline
4.2.1. Analysis by Type of Protein Degrader
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Target Indication
4.2.5. Analysis by Type of Target Protein
4.2.6. Analysis by Type of Target Enzyme
4.2.7. Analysis by Type of Therapy
4.2.8. Analysis by Route of Administration
 
4.3. Targeted Protein Degradation-based Therapeutics and Technologies: List of Research Tools / Key Technology Platforms
 
4.4. Targeted Protein Degradation-based Therapeutics and Technologies: Developer Landscape
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Size of Company
4.4.3. Analysis by Type of Protein Degrader
4.4.4. Analysis by Location of Headquarters
4.4.5. Leading Developers: Analysis by Number of Drug Candidates
 
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Developers with Late-stage Clinical Candidates
5.2.1. Radius Health
5.2.1.1. Company Overview
5.2.1.2. Financial Information
5.2.1.3. Targeted Protein Degradation-based Drug Portfolio
5.2.1.3.1. Elacestrant (RAD1901)
5.2.1.4. Recent Developments and Future Outlook
 
5.2.2. Celgene
5.2.2.1. Company Overview
5.2.2.2. Financial Information
5.2.2.3. Targeted Protein Degradation-based Drug Portfolio
5.2.2.3.1. Avadomide (CC-122)
5.2.2.3.2. Iberdomide (CC-220)
5.2.2.4. Recent Developments and Future Outlook
 
5.2.3. Sanofi Genzyme
5.2.3.1. Company Overview
5.2.3.2. Financial Information
5.2.3.3. Targeted Protein Degradation-based Drug Portfolio
5.2.3.3.1. SAR439859
5.2.3.4. Recent Developments and Future Outlook
 
5.3. Developers with Preclinical / Early-stage Clinical Candidates
5.3.1. Arvinas
5.3.2. Captor Therapeutics
5.3.3. Genentech
5.3.4. Kymera Therapeutics
5.3.5. Mission Therapeutics
5.3.6. Progenra
5.3.7. Zenopharm
 
6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Targeted Protein Degradation-based Therapeutics and Technologies: List of Clinical Trials
6.3.1. Analysis by Trial Registration Year
6.3.2. Geographical Analysis by Number of Clinical Trials
6.3.3. Geographical Analysis by Enrolled Patient Population
6.3.4. Analysis by Type of Protein Degrader
6.3.5. Analysis by Phase of Development
6.3.6. Analysis by Study Design
6.3.7. Analysis by Type of Sponsor / Collaborator
6.3.8. Most Active Players: Analysis by Number of Registered Trials
6.3.9. Analysis by Trial Focus 
6.3.10. Analysis by Therapeutic Area
6.3.11. Analysis by Clinical Endpoints
 
7. KOL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Targeted Protein Degradation-based Therapeutics and Technologies: List of Principal Investigators Involved in Clinical Trials
7.3.1. Analysis by Designation
7.3.2. Analysis by Phase of Development and Type of Protein Degrader
7.3.3. Analysis by Focus Therapeutic Area
7.3.4. Analysis by Type of Organization
7.3.5. Analysis by Location of Organization
7.3.6. Leading Organizations: Analysis by Number of Affiliated Principal Investigators
 
7.4. Prominent Key Opinion Leaders (KOLs)
7.5. KOL Benchmarking: Roots Analysis versus Third Party Scoring (ResearchGate Score)
7.6. Profiles of Most Active KOLs
7.6.1. Profile: KOL A (Barbara Ann Karmanos Cancer Center)
7.6.2. Profile: KOL B (Celgene)
7.6.3. Profile: KOL C (Feinberg School of Medicine, Northwestern University)
7.6.4. Profile: KOL D (Royal Marsden NHS Foundation Trust)
7.6.5. Profile: KOL E (Samus Therapeutics)
7.6.6. Profile: KOL F (Stanford Women Cancer Center)
7.6.7. Profile: KOL G (University of North Carolina at Chapel Hill)
7.6.8. Profile: KOL H (University of Toledo)
 
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Targeted Protein Degradation-based Therapeutics and Technologies: Recent Collaborations and Partnerships
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Protein Degrader
8.3.4. Analysis by Technology Platform
8.3.5. Analysis by Therapeutic Area
8.3.6. Most Active Players: Analysis by Number of Partnerships
8.3.7. Geographical Analysis
8.3.7.1. Most Active Players: Regional Analysis by Number of Partnerships
8.3.7.2. Intercontinental and Intracontinental Agreements
 
9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Targeted Protein Degradation-based Therapeutics and Technologies: Recent Funding Instances
9.3.1. Analysis by Number of Funding Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Number of Funding Instances and Amount Invested across Different Types of Degraders
9.3.5. Analysis by Number of Funding Instances and Amount Invested across Different Therapeutic Areas
9.3.6. Analysis by Amount Invested across Different Technology Platforms
9.3.7. Most Active Players: Analysis by Number of Funding Instances and Amount Invested
9.3.8. Most Active Investors: Analysis by Participation
9.3.9. Geographical Analysis by Amount Invested
9.4. Concluding Remarks
 
10. MARKET SIZING AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions and Forecast Methodology
10.3. Targeted Protein Degradation-based Therapeutics and Technologies: Information on Licensing Deals
 
10.4. Overall Targeted Protein Degradation-based Therapeutics and Technologies Market, 2020-2030
10.4.1. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Type of Protein Degrader
10.4.1.1. Targeted Protein Degradation-based Therapeutics and Technologies Market for Degronimids, 2020-2030
10.4.1.2. Targeted Protein Degradation-based Therapeutics and Technologies Market for IMiDs, 2020-2030
10.4.1.3. Targeted Protein Degradation-based Therapeutics and Technologies Market for PROTACs, 2020-2030
10.4.1.4. Targeted Protein Degradation-based Therapeutics and Technologies Market for SARDs, 2020-2030
10.4.1.5. Targeted Protein Degradation-based Therapeutics and Technologies Market for SERDs, 2020-2030
10.4.1.6. Targeted Protein Degradation-based Therapeutics and Technologies Market for Specific BET and DUB Inhibitors, 2020-2030
 
10.4.2. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Therapeutic Area
10.4.2.1. Targeted Protein Degradation-based Therapeutics and Technologies Market for Inflammatory Disorders, 2020-2030
10.4.2.2. Targeted Protein Degradation-based Therapeutics and Technologies Market for Neurological Disorders, 2020-2030
10.4.2.3. Targeted Protein Degradation-based Therapeutics and Technologies Market for Oncological Disorders, 2020-2030
10.4.2.4. Targeted Protein Degradation-based Therapeutics and Technologies Market for Respiratory Disorders, 2020-2030
10.4.2.5. Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Therapeutic Areas, 2020-2030
 
10.4.3. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Route of Administration
10.4.3.1. Targeted Protein Degradation-based Therapeutics and Technologies Market for Oral Route, 2020-2030
10.4.3.2. Targeted Protein Degradation-based Therapeutics and Technologies Market for Intravenous Route, 2020-2030
10.4.3.3. Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Routes, 2020-2030
 
10.4.4. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Geography
10.4.4.1. Targeted Protein Degradation-based Therapeutics and Technologies Market in North America, 2020-2030
10.4.4.2. Targeted Protein Degradation-based Therapeutics and Technologies Market in Europe, 2020-2030
10.4.4.3. Targeted Protein Degradation-based Therapeutics and Technologies Market in Asia-Pacific, 2020-2030
 
10.4.5. Targeted Protein Degradation-based Therapeutics and Technologies Market: Share of Key Contributing Technologies, 2020-2030
 
11. EXECUTIVE INSIGHTS
 
12. CONCLUDING REMARKS
12.1. Chapter Overview
12.2. Key Takeaways
 
13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1 Important Mechanisms of Protein Surveillance
Figure 3.2 Common Types of Post-translational Modifications
Figure 3.3 Mechanism-based Analogies in Phosphorylation and Ubiquitination
Figure 3.4 Key Differences in Phosphorylation and Ubiquitination
Figure 3.5 Types of Proteins Associated with Ubiquitin
Figure 3.6 Genetic Evolution of the UPS in Eukaryotes
Figure 3.6 Key Components of the UPS
Figure 3.7 Key Steps Involved in Protein Degradation via the Ubiquitin-Proteasome Pathway
Figure 3.8 Different Modes of Ubiquitination
Figure 3.9 Biological Functions of Ubiquitination
Figure 3.10 Disease Development Process in the UPS
Figure 3.11 Key Therapeutic Areas Targeted by UPS Modulating Drug Candidates
Figure 3.12 Key Differences Between Protein Degrader and Protein Inhibitor
Figure 3.13 Historical Evolution of Targeted Protein Degradation
Figure 3.14 Types of Protein Degraders
Figure 3.15 Mechanism of Action of PROTACs
Figure 3.16 Mechanism of Action of ENDTACs
Figure 3.17 Mechanism of Action of LYTACs
Figure 3.18 Mechanism of Action of PHOTACs
Figure 3.19 Mechanism of Action of Epichaperome Inhibitors
Figure 3.20 Mechanism of Action of Hydrophobic Tags
Figure 3.21 Mechanism of Action of IMiDs
Figure 3.22 Mechanism of Action of Molecular Glues
Figure 3.23 Mechanism of Action of Protein Homeostatic Modulators
Figure 3.24 Mechanism of Action of SHRDs
Figure 3.25 Mechanism of Action of SNIPERs
Figure 3.26 Key Growth Drivers and Roadblocks Related to Targeted Protein Degraders
Figure 4.1 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Type of Protein Degrader
Figure 4.2 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Phase of Development
Figure 4.3 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Phase of Development and Type of Protein Degrader
Figure 4.4 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Therapeutic Area
Figure 4.5 Popular Indications: Distribution by Number of Drug Candidates
Figure 4.6 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Therapeutic Area and Type of Protein Degrader
Figure 4.7 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Therapeutic Area and Phase of Development
Figure 4.8 Popular Target Enzymes: Distribution by Number of Drug Candidates
Figure 4.9 Popular Target Proteins: Distribution by Number of Drug Candidates 
Figure 4.10 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Target Protein and Type of Protein Degrader
Figure 4.11 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Target Protein and Phase of Development
Figure 4.12 Targeted Protein Degradation-based Therapeutics and Technologies: Grid Analysis
Figure 4.13 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Type of Therapy
Figure 4.14 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Route of Administration
Figure 4.15 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution of Industry Players by Year of Establishment
Figure 4.16 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution of Industry Players by Location of Headquarters
Figure 4.17 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution of Industry Players by Size of Company
Figure 4.18 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution of Industry Players by Type of Protein Degrader
Figure 4.19 Targeted Protein Degradation-based Therapeutics and Technologies: Geographical Distribution of Industry Players by Type of Protein Degrader
Figure 4.20 Leading Developers: Distribution by Number of Drug Candidates
Figure 5.1 Radius Health: Net Revenues, FY 2014 – Q3 2019 (USD Million)
Figure 5.2 Celgene: Net Revenues, FY 2014 – Q3 2019 (USD Million)
Figure 5.3 Sanofi Genzyme: Net Revenues, FY 2014 – Q3 2019 (USD Million)
Figure 6.1. Clinical Trials: Distribution by Trial Status
Figure 6.2 Clinical Trials: Cumulative Distribution by Registration Year, Pre-2012-Q3 2019
Figure 6.3 Clinical Trials: Geographical Distribution of Trials
Figure 6.4 Clinical Trials: Geographical Distribution of Enrolled Patient Population
Figure 6.5 Clinical Trials: Distribution by Trial Phase
Figure 6.6 Clinical Trials: Distribution by Type of Protein Degrader
Figure 6.7 Clinical Trials: Distribution by Type of Protein Degrader and Trial Phase
Figure 6.8 Clinical Trials: Distribution by Therapeutic Area
Figure 6.9 Popular Indications: Distribution by Number of Trials
Figure 6.10 Clinical Trials: Distribution by Popular Indications and Phase of Development
Figure 6.11 Clinical Trials: Distribution by Therapeutic Area, Type of Protein Degrader, Trial Phase and Trial Registration Year
Figure 6.12 Clinical Trials: Distribution by Study Design
Figure 6.13 Clinical Trials: Distribution by Type of Sponsor / Collaborator
Figure 6.14 Most Active Players: Distribution by Number of Registered Trials
Figure 6.15 Clinical Trials: Benchmarking by Number of Trials across Popular Indications
Figure 6.16 Clinical Trials: Popular Keywords
Figure 6.17 Clinical Trials: Distribution of Clinical Endpoints by Trial Phase
Figure 7.1 KOLs: Geographical Distribution of Principal Investigators
Figure 7.2 KOLs: Distribution by Designation
Figure 7.3 KOLs: Distribution by Phase of Development and Type of Protein Degrader
Figure 7.4 KOLs: Distribution by Therapeutic Area
Figure 7.5 KOLs: Distribution by Type of Organization
Figure 7.6 KOLs: Distribution by Location of Organization
Figure 7.7 Leading Organizations: Distribution by Number of Principal Investigators
Figure 7.8 KOLs: Dot-Plot of Principal Investigators
Figure 7.9 KOL Benchmarking: Roots Analysis versus Third Party Scoring
Figure 7.10 Most Prominent KOLs
Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-Q3 2019
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership 
Figure 8.3 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Protein Degrader
Figure 8.5 Partnerships and Collaborations: Year-wise Trend by Type of Protein Degrader
Figure 8.6 Partnerships and Collaborations: Distribution by Type of Protein Degrader and Partnership Model
Figure 8.7 Leading Technology Platforms: Distribution by Number of Partnerships
Figure 8.8 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 8.9 Partnerships and Collaborations: Distribution by Therapeutic Area and Partnership Model
Figure 8.10 Most Active Players: Distribution by Number of Partnerships
Figure 8.11 Most Active Players: Regional Distribution by Number of Partnerships
Figure 8.12 Partnerships and Collaborations: Regional Distribution (Intercontinental and Intracontinental Agreements)
Figure 9.1 Funding and Investments: Distribution of Companies by Year of Establishment and Type of Funding, 2014-Q3 2019
Figure 9.2 Funding and Investments: Distribution of Amount Invested by Focus Area and Type of Funding, 2014-Q3 2019
Figure 9.3 Funding and Investments: Cumulative Year-wise Trend, 2014-Q3 2019
Figure 9.4 Funding and Investments: Cumulative Amount Invested by Year, 2014-Q3 2019 (USD Million)
Figure 9.5 Funding and Investments: Distribution by Type of Funding
Figure 9.6 Funding and Investments: Distribution by Amount Invested and Type of Funding (USD Million)
Figure 9.7 Funding and Investments: Summary of Investments, 2014-Q3 2019 (USD Million)
Figure 9.8 Popular Protein Degraders: Distribution by Number of Funding Instances
Figure 9.9 Popular Protein Degraders: Distribution by Amount Invested (USD Million)
Figure 9.10 Funding and Investments: Year-wise Trend of Amount Invested across Different Degraders, 2014-Q3 2019 (USD Million)
Figure 9.11 Popular Technology Platforms: Distribution by Amount Invested (USD Million)
Figure 9.12 Popular Therapeutic Areas: Distribution by Number of Funding Instances
Figure 9.13 Popular Therapeutic Areas: Distribution by Number of Funding Instances across Different Degraders
Figure 9.14 Popular Therapeutic Areas: Distribution by Amount Invested (USD Million)
Figure 9.15 Most Active Players: Distribution by Number of Instances
Figure 9.16 Most Active Players: Distribution by Capital Amount Raised (USD Million)
Figure 9.17 Most Active Investors: Distribution by Number of Instances
Figure 9.18 Funding and Investments: Geographical Distribution by Amount Invested (USD Million)
Figure 9.19 Funding and Investment Summary
Figure 10.1 Targeted Protein Degradation-based Therapeutics and Technologies: Information on Licensing Deals
Figure 10.2 Targeted Protein Degradation-based Therapeutics and Technologies: Average Value and Volume of Upfront Payments (Units, USD Million)
Figure 10.3 Targeted Protein Degradation-based Therapeutics and Technologies: Average Value and Volume of Milestone Payments (Units, USD Million)
Figure 10.4 Overall Targeted Protein Degradation-based Therapeutics and Technologies Market, 2020-2030 (USD Million)
Figure 10.5 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Type of Protein Degrader, 2020-2030 (USD Million)
Figure 10.6 Targeted Protein Degradation-based Therapeutics and Technologies Market for Degronimids, 2020-2030 (USD Million)
Figure 10.7 Targeted Protein Degradation-based Therapeutics and Technologies Market for IMiDs, 2020-2030 (USD Million)
Figure 10.8 Targeted Protein Degradation-based Therapeutics and Technologies Market for PROTACs, 2020-2030 (USD Million)
Figure 10.9 Targeted Protein Degradation-based Therapeutics and Technologies Market for SARDs, 2020-2030 (USD Million)
Figure 10.10 Targeted Protein Degradation-based Therapeutics and Technologies Market for SERDs, 2020-2030 (USD Million)
Figure 10.11 Targeted Protein Degradation-based Therapeutics and Technologies Market for Specific BET and DUB Inhibitors, 2020-2030 (USD Million)
Figure 10.12 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Therapeutic Area, 2020-2030 (USD Million)
Figure 10.13 Targeted Protein Degradation-based Therapeutics and Technologies Market for Inflammatory Disorders, 2020-2030 (USD Million)
Figure 10.14 Targeted Protein Degradation-based Therapeutics and Technologies Market for Neurological Disorders, 2020-2030 (USD Million)
Figure 10.15 Targeted Protein Degradation-based Therapeutics and Technologies Market for Oncological Disorders, 2020-2030 (USD Million)
Figure 10.16 Targeted Protein Degradation-based Therapeutics and Technologies Market for Respiratory Disorders, 2020-2030 (USD Million)
Figure 10.17 Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Therapeutic Areas, 2020-2030 (USD Million)
Figure 10.18 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 10.19 Targeted Protein Degradation-based Therapeutics and Technologies Market for Oral Route, 2020-2030 (USD Million)
Figure 10.20 Targeted Protein Degradation-based Therapeutics and Technologies Market for Intravenous Route, 2020-2030 (USD Million)
Figure 10.21 Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Routes, 2020-2030 (USD Million)
Figure 10.22 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Region, 2020-2030 (USD Million)
Figure 10.23 Targeted Protein Degradation-based Therapeutics and Technologies Market in North America, 2020-2030 (USD Million)
Figure 10.24 Targeted Protein Degradation-based Therapeutics and Technologies Market in Europe, 2020-2030 (USD Million)
Figure 10.25 Targeted Protein Degradation-based Therapeutics and Technologies Market in Asia-Pacific, 2020-2030 (USD Million)
Figure 10.26 Targeted Protein Degradation-based Therapeutics and Technologies Market for Key Contributing Technologies, 2020-2030 (USD Million) 

List of Tables

Table 3.1 Structural Classification of Ubiquitin  
Table 4.1 Targeted Protein Degradation-based Therapeutics and Technologies: Development Pipeline
Table 4.2 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Therapeutic Area and Phase of Development
Table 4.3 Targeted Protein Degradation-based Therapeutics and Technologies: Information on Target Enzyme, Target Protein, Signaling Pathway, Type of Therapy and Route of Administration
Table 4.4 Targeted Protein Degradation-based Therapeutics and Technologies: Information on Marketed First Generation Protein Degraders
Table 4.5 Targeted Protein Degradation-based Therapeutics and Technologies: Information on Research Tools / Key Technology Platforms
Table 4.6 Targeted Protein Degradation-based Therapeutics and Technologies: Developer Landscape
Table 5.1 Radius Health: Key Highlights
Table 5.2 Drug Profile: Elacestrant (RAD1901)
Table 5.3 Radius Health: Recent Developments and Future Outlook
Table 5.4 Celgene: Key Highlights
Table 5.5 Drug Profile: Avadomide (CC-122)
Table 5.6 Drug Profile: Iberdomide (CC-220)
Table 5.7 Celgene: Recent Developments and Future Outlook
Table 5.8 Sanofi Genzyme: Key Highlights
Table 5.9 Drug profile: SAR439859
Table 5.10 Sanofi Genzyme: Recent Developments and Future Outlook
Table 5.11 Arvinas: Key Highlights
Table 5.12 Captor Therapeutics: Key Highlights
Table 5.13 Genentech: Key Highlights
Table 5.14 Kymera Therapeutics: Key Highlights
Table 5.15 Mission Therapeutics: Key Highlights
Table 5.16 Progenra: Key Highlights
Table 5.17 Zenopharm: Key Highlights
Table 6.1 Targeted Protein Degradation-based Therapeutics and Technologies: List of Clinical Trials
Table 6.2 Clinical Trials: Distribution by Registration Year and Type of Protein Degrader
Table 6.3 Clinical Trials: Popular Clinical Endpoints by Phase of Development
Table 7.1 Targeted Protein Degradation-based Therapeutics and Technologies: List of Principal Investigators
Table 7.2 KOLs: Roots Analysis Proprietary Scoring System
Table 7.3 Profile: KOL A (Barbara Ann Karmanos Cancer Center)
Table 7.4 Profile: KOL B (Celgene)
Table 7.5 Profile: KOL C (Feinberg School of Medicine, Northwestern University)
Table 7.6 Profile: KOL D (Royal Marsden NHS Foundation Trust)
Table 7.7 Profile: KOL E (Samus Therapeutics)
Table 7.8 Profile: KOL F (Stanford Women Cancer Center)
Table 7.9 Profile: KOL G (University of North Carolina at Chapel Hill)
Table 7.10 Profile: KOL H (University of Toledo)
Table 8.1 Targeted Protein Degradation-based Therapeutics and Technologies: List of Partnerships, 2014-Q3 2019
Table 8.2 Most Active Players: Regional Distribution by Number of Partnerships
Table 9.1 Targeted Protein Degradation-based Therapeutics and Technologies: List of Funding Instances, 2014-Q3 2019
Table 9.2 Targeted Protein Degradation-based Therapeutics and Technologies: Summary of Investments
Table 11.1 Xios Therapeutics: Key Highlights
Table 12.1 Targeted Protein Degradation-based Therapeutics and Technologies: Key Takeaways of the Report
Table 13.1 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Type of Protein Degrader
Table 13.2 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Phase of Development
Table 13.3 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Phase of Development and Type of Protein Degrader
Table 13.4 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Therapeutic Area
Table 13.5 Popular Indications: Distribution by Number of Drug Candidates
Table 13.6 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Therapeutic Area and Type of Protein Degrader
Table 13.7 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Therapeutic Area and Phase of Development
Table 13.8 Popular Target Enzymes: Distribution by Number of Drug Candidates
Table 13.9 Popular Target Proteins: Distribution by Number of Drug Candidates 
Table 13.10 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Target Protein and Type of Protein Degrader
Table 13.11 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Target Protein and Phase of Development
Table 13.12 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Type of Therapy
Table 13.13 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Route of Administration
Table 13.14 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution of Industry Players by Year of Establishment
Table 13.15 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution of Industry Players by Location of Headquarters
Table 13.16 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution of Industry Players by Size of Company
Table 13.17 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution of Industry Players by Type of Protein Degrader
Table 13.18 Targeted Protein Degradation-based Therapeutics and Technologies: Geographical Distribution of Industry Players by Type of Protein Degrader
Table 13.19 Leading Developers: Distribution by Number of Drug Candidates
Table 13.21 Radius Health: Net Revenues, FY 2014 – Q3 2019 (USD Million)
Table 13.22 Celgene: Net Revenues, FY 2014 – Q3 2019 (USD Million)
Table 13.23 Sanofi Genzyme: Net Revenues, FY 2014 – Q3 2019 (USD Million)
Table 13.24 Clinical Trials: Distribution by Trial Status
Table 13.25 Clinical Trials: Cumulative Distribution by Registration Year, Pre-2012-Q3 2019
Table 13.26 Clinical Trials: Geographical Distribution of Trials
Table 13.27 Clinical Trials: Geographical Distribution of Enrolled Patient Population
Table 13.28 Clinical Trials: Distribution by Trial Phase
Table 13.29 Clinical Trials: Distribution by Type of Protein Degrader
Table 13.30 Clinical Trials: Distribution by Type of Protein Degrader and Trial Phase
Table 13.31 Clinical Trials: Distribution by Therapeutic Area
Table 13.32 Popular Indications: Distribution by Number of Trials
Table 13.33 Clinical Trials: Distribution by Popular Indications and Phase of Development
Table 13.34 Clinical Trials: Distribution by Study Design
Table 13.35 Clinical Trials: Distribution by Type of Sponsor / Collaborator
Table 13.36 Most Active Players: Distribution by Number of Registered Trials
Table 13.37 Clinical Trials: Benchmarking by Number of Trials across Popular Indications
Table 13.38 Clinical Trials: Distribution of Clinical Endpoints by Trial Phase
Table 13.39 KOLs: Distribution by Designation
Table 13.40 KOLs: Distribution by Phase of Development and Type of Protein Degrader
Table 13.41 KOLs: Distribution by Therapeutic Area
Table 13.42 KOLs: Distribution by Type of Organization
Table 13.43 KOLs: Distribution by Location of Organization
Table 13.44 Leading Organizations: Distribution by Number of Principal Investigators
Table 13.45 KOL Benchmarking: Roots Analysis versus Third Party Scoring
Table 13.46 Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-Q3 2019
Table 13.47 Partnerships and Collaborations: Distribution by Type of Partnership 
Table 13.48 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Table 13.49 Partnerships and Collaborations: Distribution by Type of Protein Degrader
Table 13.50 Partnerships and Collaborations: Year-wise Trend by Type of Protein Degrader
Table 13.51 Partnerships and Collaborations: Distribution by Type of Protein Degrader and Partnership Model
Table 13.52 Leading Technology Platforms: Distribution by Number of Partnerships
Table 13.53 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 13.54 Partnerships and Collaborations: Distribution by Therapeutic Area and Partnership Model
Table 13.55 Most Active Players: Distribution by Number of Partnerships
Table 13.56 Most Active Players: Regional Distribution by Number of Partnerships
Table 13.57 Partnerships and Collaborations: Regional Distribution (Intercontinental and Intracontinental Agreements)
Table 13.58 Funding and Investments: Distribution of Companies by Year of Establishment and Type of Funding, 2014-Q3 2019
Table 13.59 Funding and Investments: Distribution of Amount Invested by Focus Area and Type of Funding, 2014-Q3 2019
Table 13.60 Funding and Investments: Cumulative Year-wise Trend, 2014-Q3 2019
Table 13.61 Funding and Investments: Cumulative Amount Invested by Year, 2014-Q3 2019 (USD Million)
Table 13.62 Funding and Investments: Distribution by Type of Funding
Table 13.63 Funding and Investments: Distribution by Amount Invested and Type of Funding (USD Million)
Table 13.64 Funding and Investments: Summary of Investments, 2014-Q3 2019 (USD Million)
Table 13.65 Popular Protein Degraders: Distribution by Number of Funding Instances
Table 13.66 Popular Protein Degraders: Distribution by Amount Invested (USD Million)
Table 13.67 Funding and Investments: Year-wise Trend of Amount Invested across Different Degraders, 2014-Q3 2019 (USD Million)
Table 13.68 Popular Technology Platforms: Distribution by Amount Invested (USD Million)
Table 13.69 Popular Therapeutic Areas: Distribution by Number of Funding Instances
Table 13.70 Popular Therapeutic Areas: Distribution by Number of Funding Instances across Different Degraders
Table 13.71 Popular Therapeutic Areas: Distribution by Amount Invested (USD Million)
Table 13.72 Most Active Players: Distribution by Number of Instances
Table 13.73 Most Active Players: Distribution by Capital Amount Raised (USD Million)
Table 13.74 Most Active Investors: Distribution by Number of Instances
Table 13.75 Funding and Investments: Geographical Distribution by Amount Invested (USD Million)
Table 13.76 Overall Targeted Protein Degradation-based Therapeutics and Technologies Market, Conservative Scenario, 2020-2030 (USD Million)
Table 13.77 Overall Targeted Protein Degradation-based Therapeutics and Technologies Market, Base Scenario, 2020-2030 (USD Million)
Table 13.78 Overall Targeted Protein Degradation-based Therapeutics and Technologies Market, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.79 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Type of Protein Degrader, Conservative Scenario, 2020-2030 (USD Million)
Table 13.80 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Type of Protein Degrader, Base Scenario, 2020-2030 (USD Million)
Table 13.81 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Type of Protein Degrader, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.82 Targeted Protein Degradation-based Therapeutics and Technologies Market for Degronimids, Conservative Scenario, 2020-2030 (USD Million)
Table 13.83 Targeted Protein Degradation-based Therapeutics and Technologies Market for Degronimids, Base Scenario, 2020-2030 (USD Million)
Table 13.84 Targeted Protein Degradation-based Therapeutics and Technologies Market for Degronimids, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.85 Targeted Protein Degradation-based Therapeutics and Technologies Market for IMiDs, Conservative Scenario, 2020-2030 (USD Million)
Table 13.86 Targeted Protein Degradation-based Therapeutics and Technologies Market for IMiDs, Base Scenario, 2020-2030 (USD Million)
Table 13.87 Targeted Protein Degradation-based Therapeutics and Technologies Market for IMiDs, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.88 Targeted Protein Degradation-based Therapeutics and Technologies Market for PROTACs, Conservative Scenario, 2020-2030 (USD Million)
Table 13.89 Targeted Protein Degradation-based Therapeutics and Technologies Market for PROTACs, Base Scenario, 2020-2030 (USD Million)
Table 13.90 Targeted Protein Degradation-based Therapeutics and Technologies Market for PROTACs, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.91 Targeted Protein Degradation-based Therapeutics and Technologies Market for SARDs, Conservative Scenario, 2020-2030 (USD Million)
Table 13.92 Targeted Protein Degradation-based Therapeutics and Technologies Market for SARDs, Base Scenario, 2020-2030 (USD Million)
Table 13.93 Targeted Protein Degradation-based Therapeutics and Technologies Market for SARDs, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.94 Targeted Protein Degradation-based Therapeutics and Technologies Market for SERDs, Conservative Scenario, 2020-2030 (USD Million)
Table 13.95 Targeted Protein Degradation-based Therapeutics and Technologies Market for SERDs, Base Scenario, 2020-2030 (USD Million)
Table 13.96 Targeted Protein Degradation-based Therapeutics and Technologies Market for SERDs, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.97 Targeted Protein Degradation-based Therapeutics and Technologies Market for Specific BET and DUB Inhibitors, Conservative Scenario, 2020-2030 (USD Million)
Table 13.98 Targeted Protein Degradation-based Therapeutics and Technologies Market for Specific BET and DUB Inhibitors, Base Scenario, 2020-2030 (USD Million)
Table 13.99 Targeted Protein Degradation-based Therapeutics and Technologies Market for Specific BET and DUB Inhibitors, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.100 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Therapeutic Area, Conservative Scenario, 2020-2030 (USD Million)
Table 13.101 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Therapeutic Area, Base Scenario, 2020-2030 (USD Million)
Table 13.102 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Therapeutic Area, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.103 Targeted Protein Degradation-based Therapeutics and Technologies Market for Inflammatory Disorders, Conservative Scenario, 2020-2030 (USD Million)
Table 13.104 Targeted Protein Degradation-based Therapeutics and Technologies Market for Inflammatory Disorders, Base Scenario, 2020-2030 (USD Million)
Table 13.105 Targeted Protein Degradation-based Therapeutics and Technologies Market for Inflammatory Disorders, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.106 Targeted Protein Degradation-based Therapeutics and Technologies Market for Neurological Disorders, Conservative Scenario, 2020-2030 (USD Million)
Table 13.107 Targeted Protein Degradation-based Therapeutics and Technologies Market for Neurological Disorders, Base Scenario, 2020-2030 (USD Million)
Table 13.108 Targeted Protein Degradation-based Therapeutics and Technologies Market for Neurological Disorders, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.109 Targeted Protein Degradation-based Therapeutics and Technologies Market for Oncological Disorders, Conservative Scenario, 2020-2030 (USD Million)
Table 13.110 Targeted Protein Degradation-based Therapeutics and Technologies Market for Oncological Disorders, Base Scenario, 2020-2030 (USD Million)
Table 13.111 Targeted Protein Degradation-based Therapeutics and Technologies Market for Oncological Disorders, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.112 Targeted Protein Degradation-based Therapeutics and Technologies Market for Respiratory Disorders, Conservative Scenario, 2020-2030 (USD Million)
Table 13.113 Targeted Protein Degradation-based Therapeutics and Technologies Market for Respiratory Disorders, Base Scenario, 2020-2030 (USD Million)
Table 13.114 Targeted Protein Degradation-based Therapeutics and Technologies Market for Respiratory Disorders, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.115 Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Therapeutic Areas, Conservative Scenario, 2020-2030 (USD Million)
Table 13.116 Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Therapeutic Areas, Base Scenario, 2020-2030 (USD Million)
Table 13.117 Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Therapeutic Areas, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.118 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Route of Administration, Conservative Scenario, 2020-2030 (USD Million)
Table 13.119 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Route of Administration, Base Scenario, 2020-2030 (USD Million)
Table 13.120 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Route of Administration, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.121 Targeted Protein Degradation-based Therapeutics and Technologies Market for Oral Route, Conservative Scenario, 2020-2030 (USD Million)
Table 13.122 Targeted Protein Degradation-based Therapeutics and Technologies Market for Oral Route, Base Scenario, 2020-2030 (USD Million)
Table 13.123 Targeted Protein Degradation-based Therapeutics and Technologies Market for Oral Route, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.124 Targeted Protein Degradation-based Therapeutics and Technologies Market for Intravenous Route, Conservative Scenario, 2020-2030 (USD Million)
Table 13.125 Targeted Protein Degradation-based Therapeutics and Technologies Market for Intravenous Route, Base Scenario, 2020-2030 (USD Million)
Table 13.126 Targeted Protein Degradation-based Therapeutics and Technologies Market for Intravenous Route, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.127 Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Routes, Conservative Scenario, 2020-2030 (USD Million)
Table 13.128 Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Routes, Base Scenario, 2020-2030 (USD Million)
Table 13.129 Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Routes, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.130 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Region, Conservative Scenario, 2020-2030 (USD Million)
Table 13.131 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Region, Base Scenario, 2020-2030 (USD Million)
Table 13.132 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Region, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.133 Targeted Protein Degradation-based Therapeutics and Technologies Market in North America, Conservative Scenario, 2020-2030 (USD Million)
Table 13.134 Targeted Protein Degradation-based Therapeutics and Technologies Market in North America, Base Scenario, 2020-2030 (USD Million)
Table 13.135 Targeted Protein Degradation-based Therapeutics and Technologies Market in North America, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.136 Targeted Protein Degradation-based Therapeutics and Technologies Market in Europe, Conservative Scenario, 2020-2030 (USD Million)
Table 13.137 Targeted Protein Degradation-based Therapeutics and Technologies Market in Europe, Base Scenario, 2020-2030 (USD Million)
Table 13.138 Targeted Protein Degradation-based Therapeutics and Technologies Market in Europe, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.139 Targeted Protein Degradation-based Therapeutics and Technologies Market in Asia-Pacific, Conservative Scenario, 2020-2030 (USD Million)
Table 13.140 Targeted Protein Degradation-based Therapeutics and Technologies Market in Asia-Pacific, Base Scenario, 2020-2030 (USD Million)
Table 13.141 Targeted Protein Degradation-based Therapeutics and Technologies Market in Asia-Pacific, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.142 Targeted Protein Degradation-based Therapeutics and Technologies Market for Key Contributing Technologies, Conservative Scenario, 2020-2030 (USD Million)
Table 13.143 Targeted Protein Degradation-based Therapeutics and Technologies Market for Key Contributing Technologies, Base Scenario, 2020-2030 (USD Million)
Table 13.144 Targeted Protein Degradation-based Therapeutics and Technologies Market for Key Contributing Technologies, Optimistic Scenario, 2020-2030 (USD Million) 

List of Companies

  1. 5AM Ventures
  2. 6 Dimensions Capital
  3. AbbVie
  4. Abingworth 
  5. Abramson Cancer Center, University of Pennsylvania
  6. Advantech Capital
  7. Aisling Capital
  8. AJU IB Investment
  9. Alexandria Venture Investments
  10. Alfred Berg
  11. Almac Discovery
  12. Altitude Life Science Ventures
  13. AM Capital
  14. Amgen
  15. Amsterdam UMC
  16. Amzak Health
  17. AnnJi Pharmaceutical
  18. ARCH Venture Partners
  19. ARENSIA Exploratory Medicine
  20. Arpeggio Biosciences
  21. Artios Pharma
  22. Arvinas
  23. Astex Pharmaceuticals
  24. AstraZeneca
  25. Atlas Venture
  26. Aurigene Discovery Technologies
  27. Avista Pharma Solutions
  28. Barbara Ann Karmanos Cancer Center
  29. Bayer
  30. Beactica
  31. BeiGene
  32. Beijing Huarong Sangel Venture Capital
  33. Bellco Capital
  34. Bessemer Venture Partners
  35. Beverly Hills Cancer Center
  36. BeyondSpring Pharmaceuticals
  37. Biogen
  38. BioRap Technologies
  39. BioStrategics Consulting
  40. BioTheryX
  41. Boehringer Ingelheim
  42. Borun Investment
  43. Boston Biochem
  44. Boxer Capital, Tavistock Group
  45. Bristol-Myers Squibb
  46. BVF Partners
  47. C4 Therapeutics
  48. Calico
  49. Calico Labs
  50. Cambridge Breast Cancer Research Unit, University of Cambridge
  51. Cambridge Enterprise
  52. Cambridge Innovation Capital
  53. Cambridge Stem Cell Institute
  54. Canaan Partners
  55. Cancer Research Technology
  56. Capital Pathology
  57. Captor Therapeutics
  58. Cardinal Partners
  59. Carmot Therapeutics
  60. Casdin Capital
  61. Cedilla Therapeutics
  62. Celgene
  63. CellCentric
  64. Cellzome
  65. Center for Molecular and Biomolecular Informatics 
  66. Centre for Clinical Hematology, Queen Elizabeth Hospital
  67. Chemical Computing Group
  68. Chengdu Dingjian
  69. Children's Hospital of Philadelphia, University of Pennsylvania
  70. China Construction Bank
  71. Chugai Pharmaceuticals
  72. Clarivate Analytics
  73. Cobro Ventures
  74. Constellation Pharmaceuticals
  75. Cormorant Asset Management
  76. Cosmo Bio
  77. Covance
  78. Cowen Private Investments
  79. Crede Capital Group
  80. CSOP Asset Management
  81. Cullgen
  82. Cyclofluidic
  83. Daegu Gyeongbuk Medical Innovation Foundation
  84. Dana-Farber Cancer Institute
  85. Deerfield Management
  86. Dorian Therapeutics
  87. Duke University
  88. EG Capital
  89. Eisai
  90. Elan Science One
  91. Eli Lilly
  92. Emeriti Bio
  93. Epiphron Capital Group
  94. Erasmus University Medical Center
  95. Eriksam Invest Aktiebolag
  96. Eshelman Ventures
  97. Eternal Thrive
  98. European Molecular Biology Laboratory
  99. Everbright Sun Hung Kai
  100. Evotec
  101. Feinberg School of Medicine, Northwestern University
  102. Fidelity Biosciences
  103. FIMECS
  104. Florida Cancer Specialists & Research Institute
  105. FORMA Therapeutics
  106. Fosun
  107. Fox Chase Cancer Center
  108. Franklin Templeton Investments
  109. Fred Hutchinson Cancer Research Center
  110. G1 Therapeutics
  111. Genentech
  112. Gilead Sciences
  113. Gladiator
  114. GlaxoSmithKline
  115. GNI Group
  116. GV
  117. GVK Biosciences
  118. H. Lee Moffitt Cancer Center and Research Institute
  119. Haisco Pharmaceutical
  120. Handelsbanken Fonder
  121. Harvard Medical School
  122. Hatteras Venture Partners
  123. HBM Healthcare Investments
  124. HealthCap
  125. HealthCare Ventures
  126. Hermed Alpha
  127. HighLight Capital
  128. Hillhouse Capital
  129. Hinova Pharmaceuticals
  130. HitGen
  131. Holy Cross Hospital
  132. Honghui Capital
  133. Horizon Discovery
  134. Horizons Venture
  135. Hybrigenics Pharma
  136. IDEAYA Biosciences
  137. ImmunoLogik
  138. Imperial Innovations 
  139. INIM Pharma
  140. Innovate UK
  141. Institute of Cancer and Genomic Sciences, University of Birmingham
  142. Institute of Immunology and Experimental Therapy, Polish Academy of Sciences
  143. InventisBio
  144. Invus
  145. IP Group
  146. Jules Bordet Institute
  147. Juno Therapeutics
  148. Kronos Bio
  149. Kymera Therapeutics
  150. Lang Sheng Investment
  151. Lilly Ventures
  152. Ling Long Private Equity
  153. Longwood Fund
  154. Lumira Capital
  155. Macroceutics
  156. Manchester Cancer Research Centre 
  157. Massachusetts General Hospital
  158. Mayo Clinic
  159. McGill University
  160. MD Anderson Cancer Center
  161. MedImmune Ventures
  162. Medivir
  163. Memorial Sloan Kettering Cancer Center
  164. Merck
  165. Mirae Asset Capital
  166. Mission Therapeutics
  167. Mitobridge
  168. Moonstone Investments
  169. Morningside Ventures
  170. Mount Sinai Hospital’s Lunenfeld-Tanenbaum Research Institute
  171. Mountain Group Partners 
  172. MRC Cambridge Stem Cell Institute
  173. MRL Ventures Fund
  174. Mubadala Ventures
  175. Nanologica
  176. National Cancer Institute
  177. National Centre for Research and Development
  178. National Institute of Genetics
  179. New China Asset Management
  180. New Enterprise Associates
  181. New Leaf Venture Partners
  182. Nextech Invest
  183. NIHR CRUK Experimental Cancer Medicine Centre
  184. Nordic Cross
  185. Novartis
  186. Novartis Institutes for BioMedical Research
  187. Novartis-Berkeley Center for Proteomics and Chemistry Technologies
  188. Nuevolution
  189. Nurix Therapeutics
  190. Nyenburgh Investment Partners
  191. Oerth Bio
  192. Ohio State University
  193. Olema Pharmaceuticals
  194. Omega Funds
  195. Oncternal Therapeutics
  196. OrbiMed
  197. Oriental Securities Capital
  198. Oxford Finance
  199. PamGene
  200. Parexel
  201. Pelago Bioscience
  202. Perceptive Advisors
  203. Pfizer
  204. Pin Therapeutics
  205. Plexium
  206. Polaris Partners
  207. PolyProx Therapeutics
  208. Profacgen
  209. Progenra
  210. Promega
  211. Prostate Cancer Foundation
  212. Proteostasis Therapeutics
  213. Providence Investment
  214. PTC Therapeutics
  215. Pudong Innotek
  216. Queen’s University
  217. RA Capital Management
  218. Radius Health
  219. Regeneron Pharmaceuticals
  220. Robert-Bosch-Hospital, Stuttgart
  221. Roche
  222. Rock Springs Capital Management
  223. Roswell Park Cancer Institute
  224. RT Capital
  225. Samus Therapeutics
  226. Sanofi Genzyme
  227. Sarah Cannon Research Institute 
  228. Sequoia Capital China
  229. Servier
  230. Shanghai Broad Resources Investment Management 
  231. Shanghai Free Trade Zone Equity Fund
  232. Shenzhen Sangel Venture Capital
  233. Shenzhen Sangel Zhichuang Investment
  234. Sirona Capital
  235. Sitryx 
  236. Sofinnova Partners
  237. Solar Capital
  238. Songhe Capital
  239. South Texas Accelerated Research Therapeutics
  240. SR One
  241. Stanford Women’s Cancer Center
  242. Stephenson Cancer Center
  243. Suzhou Broad Resources
  244. Suzhou Pioneer Pharmaceutical
  245. SV Health Investors
  246. SV Torch
  247. Swedbank Robur
  248. Sygnature Discovery
  249. Takeda Pharmaceutical
  250. Tavistock Life Sciences
  251. Tetralogic Pharmaceuticals
  252. The Column Group
  253. The DMS Group
  254. The Institute of Cancer Research
  255. The Kraft Group
  256. The Michael J. Fox Foundation
  257. The Netherlands Cancer Institute
  258. The Rockefeller University
  259. The Royal Marsden NHS Foundation Trust
  260. The Silverstein Foundation for Parkinson’s with GBA
  261. Theravance Biopharma
  262. Third Rock Ventures
  263. Tianyi Hong Kong Development
  264. Tokalas
  265. Trinitas Capital
  266. UbiQ Bio
  267. Ubiquigent
  268. UCLA Jonsson Comprehensive Cancer Center
  269. Ultragenyx
  270. Unionen
  271. Unity Biotechnology
  272. Universitair Ziekenhuis Leuven
  273. University Hospital Erlangen
  274. University Medical Center Groningen
  275. University of California, Berkeley
  276. University of Chicago
  277. University of Dundee
  278. University of Illinois
  279. University of Kentucky
  280. University of Liverpool
  281. University of North Carolina at Chapel Hill
  282. University of Oxford
  283. University of Strathclyde
  284. University of Tennessee Research Foundation
  285. University of Toledo
  286. University of Washington
  287. Vagelos College of Physicians and Surgeons, Columbia University
  288. Verastem Oncology
  289. Versant Ventures
  290. Vertex Pharmaceuticals
  291. Vicore Pharma
  292. Vida Ventures
  293. Vividion Therapeutics
  294. Weill Medical College of Cornell University
  295. Woodford Patient Capital Trust
  296. Wroclaw Research Center EIT+
  297. WuXi AppTec
  298. Wyeth
  299. X-Chem
  300. Xios Therapeutics
  301. Yale University
  302. Yissum
  303. Yuanhe Holding
  304. Yuansheng Venture Capital
  305. Zenopharm

 

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com